Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Tetsuji, Terazawa"'
Autor:
Shunji Endo, Tetsuji Terazawa, Masahiro Goto, Ryo Tanaka, Takeshi Kato, Kazumasa Fujitani, Hisato Kawakami, Daisuke Sakai, Yukinori Kurokawa, Toshimasa Tsujinaka, Toshio Shimokawa, Taroh Satoh
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-8 (2022)
Abstract Background Large type 3 and type 4 gastric cancers have extremely poor prognoses. To address this, neoadjuvant chemotherapy may be a promising approach. The phase III JCOG0501 study, conducted to confirm the superiority of neoadjuvant S-1 pl
Externí odkaz:
https://doaj.org/article/64021a2d99e14bdca8abdc549a131c7c
Autor:
Yoshihiro Inoue, Masatsugu Ishii, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Tetsuji Terazawa, Akira Asai, Shinya Fukunishi, Kazuhide Higuchi, Kazuhisa Uchiyama
Publikováno v:
Contemporary Oncology, Vol 24, Iss 3, Pp 172-176 (2020)
Externí odkaz:
https://doaj.org/article/5bde1f44e15040948f57aa6b0baccda7
Autor:
Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Yoshihiro Matsubara, Taroh Satoh
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-5 (2019)
Abstract Background A cytotoxic chemotherapeutic regimen is not routinely recommended for frail elderly patients with unresectable colorectal cancer (CRC) because of susceptibility to treatment. Panitumumab is a monoclonal antibody targeting the epid
Externí odkaz:
https://doaj.org/article/2633da71f54a4a608ce4d63070f9d032
Autor:
Shogen Boku, Hironaga Satake, Takashi Ohta, Seiichiro Mitani, Kentaro Kawakami, Yozo Suzuki, Toshihiko Matsumoto, Tetsuji Terazawa, Eiki Yamazaki, Hiroko Hasegawa, Tatsuki Ikoma, Mamoru Uemura, Toshifumi Yamaguchi, Atsushi Naito, Yasunobu Ishizuka, Yukinori Kurokawa, Daisuke Sakai, Hisato Kawakami, Toshio Shimokawa, Toshimasa Tsujinaka, Takeshi Kato, Taroh Satoh, Yoshinori Kagawa
Publikováno v:
Future Oncology. 18:4153-4160
The BRAF V600E mutation accounts for approximately 5% of colorectal cancer (CRC) cases and is an extremely poor prognostic factor. However, there are no clear recommendations regarding first-line therapy for patients with early recurrent BRAF V600E-m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b429581ff2388488465702120619245e
https://doi.org/10.2217/fon-2022-0949
https://doi.org/10.2217/fon-2022-0949
Autor:
Jun Watanabe, Tetsuji Terazawa, Shiho Yamane, Hirotaka Kazama, Hiroyuki Uetake, Takayuki Yoshino
Publikováno v:
International Journal of Clinical Oncology. 28:130-138
Background Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting. Methods This post-marketing survei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29adab9328379f142ecb56fbacf09870
https://doi.org/10.1007/s10147-022-02259-w
https://doi.org/10.1007/s10147-022-02259-w
Autor:
Takako, Ikegami, Hiroki, Nishikawa, Masahiro, Goto, Fukutaro, Shimamoto, Tetsuji, Terazawa, Toshifumi, Yamaguchi, Eiki, Yamasaki, Ken, Asaishi, Shiro, Nakamura, Kazuhide, Higuchi
Publikováno v:
Journal of Cancer. 13:3477-3484
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a681decf591d2f597f0b1d13d51db8b1
https://doi.org/10.7150/jca.78407
https://doi.org/10.7150/jca.78407
Autor:
Toshifumi Yamaguchi, Motoki Yoshida, Hisato Kawakami, Takayuki Kii, Hiroko Hasegawa, Takahiro Miyamoto, Tetsuji Terazawa, Fukutaro Shimamoto, Masayoshi Yasui, Daisuke Sakai, Toshio Shimokawa, Yukinori Kurokawa, Masahiro Goto, Taroh Satoh
Publikováno v:
Gastrointest Tumors
Introduction: Previous prospective studies suggest that the sequential use of cytotoxic agents, such as oxaliplatin, in patients with metastatic colorectal cancer (mCRC) has the potential to improve prognosis and maintain quality of life than combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6fbe943133470a9e71415b4ca6345d7
https://doi.org/10.1159/000522610
https://doi.org/10.1159/000522610
Autor:
EIKI YAMASAKI, FUKUTARO SHIMAMOTO, HIROKI NISHIKAWA, MASAHIRO GOTO, MITSUHIKO IWAMOTO, KOSEI KIMURA, AKIRA UKIMURA, NAOFUMI OOSAKA, KOHEI TANIGUCHI, FUMIHITO ONO, TETSUJI TERAZAWA, TOSHIFUMI YAMAGUCHI, KEN ASAISHI, TAKAKO IKEGAMI, KAZUHISA UCHIYAMA, SHIRO NAKAMURA, KAZUHIDE HIGUCHI
Publikováno v:
In Vivo
Background/Aim: To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). Patients and Methods: COVID-19 anti-spike protein antibody levels were measured before the fir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c481764c204061fd17818e0a98536c69
https://europepmc.org/articles/PMC9677789/
https://europepmc.org/articles/PMC9677789/
Autor:
Hisateru Yasui, Naohiro Okano, Hideaki Bando, Tomoko Jogo, Takayuki Yoshino, Taroh Satoh, Satoshi Fujii, Yoshiaki Nakamura, Eiji Shinozaki, Takanobu Yamada, Akihito Tsuji, Hiroki Hara, Takashi Ohta, Yoshito Komatsu, Yoshiyuki Yamamoto, Eiji Oki, Takeshi Kawakami, Hiroya Taniguchi, Taito Esaki, Yu Sunakawa, Nobuhisa Matsuhashi, Tomohiro Nishina, Takeshi Kato, Koushiro Ohtsubo, Toshihiko Doi, Kohei Shitara, Justin I. Odegaard, Tetsuji Terazawa
Publikováno v:
Clinical Cancer Research. 27:5619-5627
Purpose: FGFR2 amplification is associated with poor prognosis in advanced gastric cancer and its subclonal heterogeneity has been revealed. Here, we examined whether circulating tumor DNA (ctDNA) was useful for detecting FGFR2 amplification and co-o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1714c6d97287bb86bcb684430a15e3b
https://doi.org/10.1158/1078-0432.ccr-21-1414
https://doi.org/10.1158/1078-0432.ccr-21-1414
Autor:
Makoto Ueno, Takuji Okusaka, Masahiro Goto, Yasunari Sakamoto, Shin Namiki, Chigusa Morizane, Dai Inoue, Shunsuke Kondo, Hiroko Hosoi, Satoshi Kobayashi, Hideki Ueno, Akihiro Ohba, Shuichi Mitsunaga, Tetsuji Terazawa, Mitsuhito Sasaki, Masafumi Ikeda
Publikováno v:
International Journal of Clinical Oncology
Background Although FOLFIRINOX is currently one of the standard therapies for chemotherapy-naïve patients with metastatic pancreatic cancer (MPC), the high rate of febrile neutropenia (FN) presents a clinical problem. This study aimed to evaluate th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a154804f2ee91ecb72b91002a400bf44
https://doi.org/10.1007/s10147-021-02001-y
https://doi.org/10.1007/s10147-021-02001-y